HSE - PCRS

Application Details

HSE Application ID

HSE100024

HTA Number

25018

HTA Link

https://www.ncpe.ie/bimekizumab-bimzelx-hta-id-25018/

Drug

bimekizumab

Brand

Bimzelx®

Applicant

UCB Pharma S.A.

Indication Applied For

Indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hidradenitis suppurativa therapy.

Application Date

06/03/2025

Marketing Authorisation Date

19/04/2024

Application Status

Proposal from Applicant Under Review

31/07/2025

Awaiting Proposal from Applicant

17/07/2025

Applicant Meeting Held with CPU

17/07/2025

Rapid Review Completed

02/04/2025

Rapid Review Commissioned

06/03/2025

Pricing and Reimbursement Application Complete

06/03/2025

New Search